Sinco Pharmaceuticals Holdings (6833) Fair Value & Analysis
Healthcare · HK · Market cap HK$325M
Fair value as of: Aug 6, 2026
From 26 valuation models · updated 4 days ago
Share price +7.5% over the past month.
A solid business, screening 121% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$0.2800). The market is more pessimistic than our downside scenario.
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 6, 2026.
How to read this chart
60‑month range HK$0.1530 – HK$2.06 · fair‑value band HK$0.2800 – HK$0.4700 · the HK$0.1720 price screens below the HK$0.3800 fair value. Dashed = 300-day average. As of Aug 6, 2026.
Analysis
Sinco Pharmaceuticals Holdings (6833) currently trades at HK$0.1720, while our model-based Fair Value estimate is HK$0.3800, implying the stock looks roughly 120.9% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Sinco Pharmaceuticals Holdings generated revenue of HK$2.1B at a net margin of 1.7%. Revenue declined 31.3% year over year. It earns a return on equity of 5.1%. The balance sheet holds a net cash position of HK$191M. Fundamentals as of Aug 6, 2026
Our scenario range runs from HK$0.2800 (bear case) to HK$0.4700 (bull case); at HK$0.1720, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 121%, 6833 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$1.21) versus Dividend Discount (HK$0.0200). Highest evidence: Growth DCF (80).
Notify me when 6833 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China.
Full company description
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange. It also provides Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections. In addition, it is involved in the research, development, and sale of pharmaceutical products; provision of warehouse facilities for pharmaceutical products; research and manufacturing of aesthetic medicine; international trade activities; consultation services for medical and biological technology; market promotion; and medical beauty services. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited operates as a subsidiary of Risun Investments Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sinco Pharmaceuticals Holdings reported revenue of HK$2.1B in FY2025 versus HK$2.0B in FY2021, a compound +0.7%/yr. Reported net income was HK$34.9M in FY2025, compounding −28.7%/yr from FY2021.
of which total revenue +11.0 pp · buybacks/dilution −5.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 6833: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Sinco Pharmaceuticals Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sinco Pharmaceuticals Holdings (6833) overvalued or undervalued?
What is the fair value of 6833?
What is the quality score of 6833?
What is the revenue of Sinco Pharmaceuticals Holdings (6833)?
What is the net profit margin of 6833?
Does Sinco Pharmaceuticals Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sinco Pharmaceuticals Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.